Document is current

Any future updates will be listed below

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)

Crossref DOI link: https://doi.org/10.1038/s41467-026-68554-6

Published Online: 2026-01-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark